Publications & Posters

Publication

BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial

https://link.springer.com/article/10.1007/s00280-026-04871-3?utm_source=rct_congratemailt&utm_medium=email&utm_campaign=nonoa_20260306&utm_content=10.1007%2Fs00280-026-04871-3
Publication

BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD

https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2025031983/566894/BET-inhibition-blunts-antibody-production-and?redirectedFrom=fulltext
Poster

Interim Analysis of PROMise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Download PDF
Oral Presentation

Novel Multifunctional Degraders of EP300/CBP and IKZF1/3 with Potent Anti-Myeloma Activity

Download PDF
Publication

Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models

https://www.nature.com/articles/s41467-025-64682-7
Poster

Interim Analysis of PROMise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Download PDF
Poster

OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF
Poster

OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models

Download PDF
Poster

OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF
Poster

OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription in mCRPC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF